Maximizing Impact With the Latest Clinical Evidence: An End-of-Year Review of Novel Therapies for HER2-Positive, HER2-Low, and HER2-Ultralow Breast Cancer
- Provider:PVI, PeerView Institute for Medical Education
- Activity Link: https://www.peerview.com/TQX
- Start Date: 2025-01-28 06:00:00
- End Date: 2025-01-28 06:00:00
- Credit Details: AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours - MOC Credit Details: ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
ABIM - 1.0 Point; Credit Type(s): Patient Safety (ABIM) - Commercial Support: Source: AstraZeneca (Any division) - Amount: 94000.0 - Is Kind Support: False Source: Daiichi Sankyo, Inc. - Amount: 90000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Medical Oncology
Subscribe
Login
0 Comments
Oldest